Lundbeck reports positive results from head-to-head study of antidepressant

Lundbeck’s antidepressant vortioxetine has reportedly demonstrated advantages compared to Pfizer’s Pristiq, which is only sold in the US.

Photo: Jens Dresling

Pharmaceutical firm Lundbeck’s antidepressant vortioxetine, which is sold under brand names Trintellix and Brintellix, has demonstrated an advantage in a head-to-head study against desvenlafaxine, which Pfizer is marketing in the US as Pristiq, Lundbeck has announced in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs